Hansens disease primarily affects the skin, nerves, and mucous membranes, leading to characteristic skin lesions and nerve damage. Hansen's disease has a long incubation period, often taking years or even decades for symptoms to manifest, which complicates early diagnosis and treatment. Despite being curable with multidrug therapy, social stigma and misconceptions surrounding the disease persist, leading to discrimination and marginalization of affected individuals. Efforts to eliminate Hansen's disease as a public health threat continue, focusing on early detection, prompt treatment, and destigmatization to ensure affected individuals receive the care and support they need.
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : Changing population immunity to COVID-19 in the context of infection, vaccination, and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : From bench to preclinical evaluation: LL-37-derived peptides for combating orthopedic infections
Vincenzo Pennone, IRCCS Galeazzi Sant’Ambrogio Hospital, Italy
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Personalized and precision medicine (PPM) as a unique healthcare model to se-cure the human healthcare, wellness and biosafety through the view of public health, network driven healthcare services and lifestyle management
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation